Bone Mineral Density News and Research

RSS

Infosys wins 2014 Simulating Reality contest for innovation in osteoporosis diagnosis

Infosys, a global leader in technology, consulting and outsourcing solutions, has been recognized as a winner in the 2014 Simulating Reality contest. The contest is organized by MSC Software, a worldwide leader of multidisciplinary simulation solutions.

13 May 2014

Study: Asthma is associated with reduced bone mineral density

Some of the 26 million Americans with asthma may also be prone to bone loss. According to a study published today in the May issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology, there seems to be association between asthma and a decrease in bone mineral density.

2 May 2014

Tips to improve bone health

As many as 52 million Americans have osteoporosis and low bone mass, and studies suggest that one in two women and up to one in four men ages 50 and older will break a bone due to osteoporosis. Osteoporosis is concerning because you can't feel your bones getting weaker, which is why it's often referred to as the "silent disease." May is National Osteoporosis Month and, since prunes have been linked to bone health, Sunsweet is urging Americans to listen to their bones this month and start taking action to keep bones strong and healthy.

29 Apr 2014

New guidelines on management and return to play of Female Athlete Triad discussed at AMSSM

The Female Athlete Triad is a medical condition often observed in physically active girls and women, and involves three components: low energy availability with or without disordered eating, menstrual dysfunction and low bone mineral density.

15 Apr 2014

Study examines link between higher screen time and bone mineral density in adolescents

Results of a study presented today at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, showed that in boys, higher screen time was adversely associated to bone mineral density (BMD) at all sites even when adjusted for specific lifestyle factors.

7 Apr 2014

High levels of protein intake and exercise improve bone structure, strength in pre-pubertal boys

A study presented during the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Seville shows that high levels of protein intake (HProt) enhance the positive impact of high physical activity (HPA) on bone structure and strength in healthy pre-pubertal boys. Researchers from the University of Geneva in Switzerland and Eindhoven University in the Netherlands tracked 176 healthy pre-pubertal boy

4 Apr 2014

Researchers evaluate cost-effectiveness of osteoporosis screening strategy using FRAX

In new research presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases today, investigators showed that an osteoporosis screening strategy using FRAX as a pre-screening tool is cost-effective if the follow up of the screening and medication adherence are optimized.

4 Apr 2014

$International Osteoporosis Foundation launches FRAX App to assess risk of osteoporotic fracture$

International Osteoporosis Foundation launches FRAX App to assess risk of osteoporotic fracture

Osteoporosis management guidelines around the world now recommend that fracture risk assessment be part of any clinical evaluation for osteoporosis. As a result, rather than relying on bone mineral density values alone, physicians now consider future fracture risk when making treatment decisions.

2 Apr 2014

$Meta-analysis study shows association between BTMs s-CTX, s-PINP and risk of future fractures$

Meta-analysis study shows association between BTMs s-CTX, s-PINP and risk of future fractures

A new study by an International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) scientific working group summarizes the clinical performance of serum procollagen type I N propeptide (s-PINP) and serum C-terminal cross-linking telopeptide of type I collagen (s-CTX) in fracture risk prediction in untreated individuals in prospective cohort studies.

5 Mar 2014

Sports medicine experts raise concern about female athlete triad syndrome

When an adolescent female patient comes to Nationwide Children's Hospital's Sports Medicine clinic, not only are these young women treated for their sports-related injury, but their sports medicine physician will also ask if they've missed any periods, because of a growing concern among female athletes.

18 Feb 2014

Aeterna Zentaris announces FDA acceptance for filing of macimorelin acetate NDA for AGHD

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.

7 Jan 2014

Overweight children face increased risk of asthma

Overweight and obesity are significant risk factors for reduced lung function in school-aged children with a history of early childhood wheezing, according to a study carried out at the University of Eastern Finland. The results also showed that the use of inhaled corticosteroids for asthma in childhood may result in reduced bone mineral density in early teenage years.

2 Jan 2014

Amgen announces romosozumab Phase 2 trial results in postmenopausal women with low BMD

Amgen and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).

2 Jan 2014

IOF Young Investigator Awards presented to five researchers at 4th Asia-Pacific Osteoporosis Meeting

Today, the International Osteoporosis Foundation recognized the outstanding work of five young researchers from China, Chinese Taipei, Hong Kong, Malaysia and Pakistan.

16 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

$Older men with low levels of vitamin B12 may have higher risk of fractures$

Older men with low levels of vitamin B12 may have higher risk of fractures

Older men who have low levels of vitamin B12 have a higher risk of having fractures. These are the findings of researchers at the Sahlgrenska Academy as a part of an international study of a total of 1000 older men.

10 Dec 2013

Exercise can improve musculoskeletal health for breast cancer survivors, say researchers

One year of exercise can ensure steady maintenance of bone density to help prevent fractures. To build and maintain muscle strength, it is best for older breast cancer survivors to follow an ongoing exercise program of resistance and impact training.

9 Dec 2013

Study compares efficacy and side effects of popular osteoporosis drugs

A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms.

4 Dec 2013

Use of testosterone therapy after angiography associated with increased risk of death

Among a group of men who underwent coronary angiography and had a low serum testosterone level, the use of testosterone therapy was associated with increased risk of death, heart attack, or ischemic stroke, according to a study in the November 6 issue of JAMA.

6 Nov 2013

Aeterna Zentaris submits macimorelin acetate NDA to FDA

Aeterna Zentaris Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration ("FDA") for its ghrelin agonist, macimorelin acetate (AEZS-130).

5 Nov 2013